Search Results

Displaying Results 1-6 of 6 "'TYME'"

May 19, 2026, 09:07 ET From Fenway to Fine Art: Kayem Launches Traveling Art Series Showcasing the Role of Hot Dogs in Historic Moments in Collaboration with the Museum of Fine Arts, Boston

by the same family for more than 115 years, the company manufactures Kayem Franks, the #1 brand of franks sold in New England. Best known for its Old Tyme Natural Casing franks, Kayem produces over 100 varieties of hot dogs and 300 varieties of deli meats, sausage and dinner hams under the Kayem, al

More news about: Kayem Foods


Apr 28, 2026, 09:13 ET Smoky, Spicy, and Limited-Time Only: Kayem Turns Up the Heat with Launch of "Cannon Fire" Hot Dog

by the same family for more than 115 years, the company manufactures Kayem Franks, the #1 brand of franks sold in New England. Best known for its Old Tyme Natural Casing franks, Kayem produces over 100 varieties of hot dogs and 300 varieties of deli meats, sausage and dinner hams under the Kayem, al

More news about: Kayem Foods


Jan 28, 2026, 17:31 ET DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight

barriers, and key breast cancer companies, including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, and others.About DelveInsightDelveInsight is a leading Business Consultant and Market Research

More news about: DelveInsight Business Research, LLP


Nov 27, 2025, 17:31 ET Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight

well as the market trends, market drivers, market barriers, and key Ewing sarcoma companies, including Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Bristol-Myers

More news about: DelveInsight Business Research LLP


Sep 29, 2025, 17:31 ET DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight

barriers, and key breast cancer companies, including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, among others. About DelveInsight DelveInsight

More news about: DelveInsight Business Research, LLP


Sep 16, 2025, 17:31 ET KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight

barriers, and key breast cancer companies, including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, among others.

More news about: DelveInsight Business Research, LLP


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.